Evidence map›Paper›PMID 40118934›Full record

ArticleScientific reports2025

Triple synergistic enhancement of breast cancer treatment via chemotherapy, chemodynamic therapy, and tumor starvation therapy driven by lipid-COF nanoparticles.

Yiya Sun, Zhenkun Ren, Zhiruo Zhang, Kexin Yang, Yufan Jin, Hanyu Deng, Yingzi Liu, Jiali Wang, Peng Ji, Peng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yiya Sun *The First Affiliated Hospital of Jinzhou Medical University, Jin Zhou, 121000, China.
Zhenkun Ren *The Third Affiliated Hospital of Jinzhou Medical University, Jin Zhou, 121000, China.
Zhiruo ZhangCollege of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, 225300, China.
Kexin YangCollege of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, 225300, China.
Yufan JinCollege of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, 225300, China.
Hanyu DengCollege of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, 225300, China.
Yingzi LiuJinzhou Medical University, Jinzhou, 121000, China.
Jiali WangJinzhou Medical University, Jinzhou, 121000, China.
Peng JiCollege of Pharmacy and Chemistry & Chemical Engineering, Taizhou University, Taizhou, 225300, China. jipeng0213@163.com.
Peng LiuThe First Affiliated Hospital of Jinzhou Medical University, Jin Zhou, 121000, China. liup@jzmu.edu.cn.

Funding

Liaoning Provincial Science and Technology Programme Joint Programme (Natural Science Foundation Project) 2024-MSLH-155National Natural Science Foundation of China 32401196Natural Science Foundation of Hangzhou 2024SZRYBH090001Natural Science Foundation Project of Taizhou Science and Technology Support Programme (Social Development) TS202402Natural Science Research of Jiangsu Higher Education Institutions of China 24KJB350011Qinglan Project of Jiangsu Province of China 2024Taizhou Fengcheng Yingcheng Talent Young Science and Technology Talent Support Project 2023Taizhou University 2025 Excellent Graduation Design (Thesis) Cultivation Program 2025PY148Taizhou University College Student Innovation and Entrepreneurship Training Program cx250129yTaizhou University College Student Innovation and Entrepreneurship Training Program cx250130yZhejiang Province Selected Funding for Postdoctoral Research Projects ZJ2023083Zhejiang Provincial Natural Science Foundation of China LQ24H300001
6 · The paper itself

Abstract

In this study, a novel cascade nano delivery system, Cur/Gox@LCOF, was developed for enhanced breast cancer therapy. The system loads curcumin (Cur) and glucose oxidase (Gox) into a lipid copper-based organic framework (LCOF) carrier for enhanced tumor therapy. The nanoparticles were characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM), and dynamic light scattering (DLS), which showed that they had a uniform spherical morphology with an average particle size of about 80 nm, displaying stable colloidal properties. The system showed excellent stability under simulated physiological conditions and exhibited pH-responsive drug release properties, contributing to the controlled release of Cur and Gox. The results of in vitro cellular experiments showed that Cur/Gox@LCOF significantly enhanced the production of reactive oxygen species (ROS), leading to significant cytotoxicity in cancer cells. In addition, the system also demonstrated enhanced therapeutic efficacy and good biocompatibility in a tumor mouse model. Thus, this study developed a nanocarrier platform for triple synergistic chemokinetic/chemotherapy/starvation therapy, which has promising applications in the efficient treatment of tumors.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCurcuminLipidsNanoparticlesAnimalsCell Line, TumorDrug CarriersDrug LiberationFemaleGlucose OxidaseHumansMiceReactive Oxygen SpeciesAntineoplastic AgentsCurcuminDrug CarriersGlucose OxidaseLipidsReactive Oxygen SpeciesBreast cancerChemodynamic therapyCopper frameworkCurcuminGlucose oxidase

Identifiers

PMID40118934
PMCPMC11928539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.